{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166341341",
    "name" : "Annotation of CPIC Guideline for acebutolol, betaxolol, bisoprolol, carvedilol, nebivolol, propranolol and CYP2D6",
    "alternateDrugAvailable" : false,
    "cancerGenome" : false,
    "crossReferences" : [
      {
        "id" : 1452518128,
        "resource" : "URL",
        "resourceId" : "https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/",
        "_url" : "https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/",
        "version" : 0
      }
    ],
    "descriptiveVideoId" : "4pjYtVaHStI",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1452553420,
        "date" : "2024-08-12T04:47:19.610-07:00",
        "description" : "Added video",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15160274,"title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502236","crossReferences":[{"id":1452681441,"resource":"PubMed Central","resourceId":"PMC11502236","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502236"},{"id":1452517521,"resource":"PubMed","resourceId":"38951961","_url":"https://www.ncbi.nlm.nih.gov/pubmed/38951961"},{"id":1452517522,"resource":"DOI","resourceId":"10.1002/cpt.3351","_url":"http://dx.doi.org/10.1002%2Fcpt.3351"}],"objCls":"Literature","pubDate":"2024-10-01T00:00:00-07:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"},{"id":1451978620,"resource":"PGx Paper Types","term":"Phenoconversion","termId":"pgxPaperTypes:1451978620"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA448011",
        "name" : "acebutolol",
        "version" : 11
      },
      {
        "objCls" : "Chemical",
        "id" : "PA448611",
        "name" : "betaxolol",
        "version" : 6
      },
      {
        "objCls" : "Chemical",
        "id" : "PA448641",
        "name" : "bisoprolol",
        "version" : 7
      },
      {
        "objCls" : "Chemical",
        "id" : "PA448817",
        "name" : "carvedilol",
        "version" : 10
      },
      {
        "objCls" : "Chemical",
        "id" : "PA151958426",
        "name" : "nebivolol",
        "version" : 6
      },
      {
        "objCls" : "Chemical",
        "id" : "PA451145",
        "name" : "propranolol",
        "version" : 15
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA128",
        "symbol" : "CYP2D6",
        "name" : "cytochrome P450 family 2 subfamily D member 6",
        "version" : 7891
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1452497860,
      "html" : "<p>There are currently no recommendations for dosing of acebutolol, betaxolol, bisoprolol, carvedilol, nebivolol or propranolol based on CYP2D6 genotypes.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1452497861,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/\" target=\"_blank\">CPIC&reg; guideline for beta-blocker therapy and CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4 and GRK5</a>.</p>\n<h3 id=\"july-2024\">July 2024</h3>\n<p>The authors of the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/\" target=\"_blank\">CPIC&reg; guideline for beta-blocker therapy and CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4 and GRK5</a> evaluated the available evidence for the use of acebutolol, betaxolol, bisoprolol, carvedilol, nebivolol and propranolol in patients carrying CYP2D6 variants. They conclude that there is insufficient evidence to guide clinical practice at this time.</p>\n<p>These guidelines are applicable to:</p>\n<ul>\n<li>adult patients</li>\n<li>pediatric patients</li>\n</ul>\n<p>Excerpts from the guideline:</p>\n<blockquote class=\"blockquote\">\n<p><em><strong>Carvedilol.</strong></em> While there is considerable evidence that CYP2D6 intermediate and poor metabolizers experience increased carvedilol exposure, there are far fewer reports in the literature [...] assessing whether this translates to clinical differences in heart rate or blood pressure response. This may, in part, be due to the fact that carvedilol is predominantly used in heart failure and is therefore slowly up-titrated, preventing many poor metabolizers from ever receiving a dose that could cause significant bradycardia. In addition, CYP2D6 metabolizes carvedilol to both pharmacologically inactive and active metabolites, which may explain why significant differences in carvedilol exposure by CYP2D6 phenotype do not seem to consistently translate into significant differences in clinical response. The committee acknowledged the assessment from the U.S. Food and Drug Administration that CYP2D6 poor metabolizers may be at a higher risk of dizziness when given carvedilol, which may be based upon unpublished data. However, considering only published results, the writing committee felt there was insufficient evidence to support carvedilol dosing recommendations based on predicted CYP2D6 phenotype (CPIC level C - no recommendation).</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>CYP2D6 poor metabolizers can experience several-fold higher plasma metoprolol, carvedilol, and nebivolol concentrations following oral administration, compared to those who are not CYP2D6 poor metabolizers. Insufficient evidence exists to indicate whether propranolol systemic exposure is similarly increased in CYP2D6 poor metabolizers.</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>Of note, beta-blockers exhibit a sigmoid dose-response relationship. Thus, increasing beta-blocker plasma concentrations beyond a certain threshold does not result in further increases in drug response</p>\n</blockquote>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961.pdf\" target=\"_blank\">Guideline publication</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961-supplement.pdf\" target=\"_blank\">Guideline supplement</a></li>\n</ul>\n<h3 id=\"table-1-recommended-therapeutic-use-of-carvedilol-in-relation-to-cyp2d6-phenotype\">Table 1: Recommended therapeutic use of carvedilol in relation to CYP2D6 phenotype</h3>\n<p><em>Adapted from Tables 1 &amp; S8 of the guideline</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype<sup>a</sup></th>\n<th>Activity score range</th>\n<th>Activity score<sup>b</sup></th>\n<th>Examples of CYP2D6 diplotypes<sup>c</sup></th>\n<th>Implications<sup>d</sup></th>\n<th>Recommendations</th>\n<th>Classification of recommendations<sup>e</sup></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Ultrarapid metabolizer</td>\n<td>&gt;2.25</td>\n<td>&gt;2.25</td>\n<td>*1/*1xN, *1/*2xN, *2/*2xN</td>\n<td>Increased metabolism of carvedilol leading to decreased drug concentrations; it is unclear whether this results in clinically significant changes in heart rate and blood pressure</td>\n<td>No recommendation for carvedilol therapy due to insufficient evidence regarding diminished clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Normal metabolizer</td>\n<td>1.25 ≤ x ≤ 2.25</td>\n<td>2.25<br/>2<br/>1.75<br/>1.5<br/>1.25</td>\n<td>*2x2*10<br/>*1/*1, *1/*2<br/>*1/*10x3<br/>*1/*17, *2/*29<br/>*1/*10, *1/*41, *1/*9</td>\n<td>Normal carvedilol metabolism</td>\n<td>Initiate standard dosing</td>\n<td>Strong</td>\n</tr>\n<tr>\n<td>Intermediate metabolizer</td>\n<td>0 &lt; x &lt; 1.25</td>\n<td>1<br/>0.75<br/>0.5<br/>0.25</td>\n<td>*1/*5<br/>*10/*17, *29/*41<br/>*10/*10, *41/*41, *10/*41<br/>*4/*10, *4/*41</td>\n<td>Decreased metabolism of carvedilol leading to small increases in drug concentrations; it is unclear whether this results in clinically significant changes in heart rate, blood pressure or major clinical outcomes</td>\n<td>No recommendation for carvedilol therapy due to insufficient evidence regarding clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Poor metabolizer</td>\n<td>0</td>\n<td>0</td>\n<td>*3/*4, *4/*4, *5/*5, *5/*6</td>\n<td>Decreased metabolism of carvedilol leading to increased drug concentrations; it is unclear whether this results in clinically significant changes in heart rate, blood pressure or major clinical outcomes</td>\n<td>No recommendation for carvedilol therapy due to insufficient evidence regarding clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Indeterminate</td>\n<td>n/a</td>\n<td>An individual carrying one or two uncertain function alleles</td>\n<td>*1/*22, *1/*25, *22/*25</td>\n<td>n/a</td>\n<td>No recommendation</td>\n<td>No recommendation</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> See the CYP2D6 Allele Frequency Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a> for ancestry-specific allele and phenotype frequencies.<br />\n<sup>b</sup> Assignment of allele function and allele activity values, including citations for allele function, can be found in the CYP2D6 Allele Definition Table and the CYP2D6 Allele Functionality Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a>. For a complete list of CYP2D6 diplotypes and predicted phenotypes, see the CYP2D6 Diplotype to Phenotype Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a>.<br />\n<sup>c</sup> Where xN represents the number of CYP2D6 gene copies.<br />\n<sup>d</sup> CYP2D6 metabolizes carvedilol to both pharmacologically inactive and active metabolites.<br />\n<sup>e</sup> Rating scheme described in the Strength of Recommendations section in the <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961-supplement.pdf\" target=\"_blank\">guideline supplement</a>.</p>\n<h3 id=\"table-2-recommended-therapeutic-use-of-acebutolol-betaxolol-bisoprolol-and-propranolol-in-relation-to-cyp2d6-phenotype\">Table 2: Recommended therapeutic use of acebutolol, betaxolol, bisoprolol and propranolol in relation to CYP2D6 phenotype</h3>\n<p><em>Adapted from Tables 1 &amp; S9 of the guideline</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype<sup>a</sup></th>\n<th>Activity score range</th>\n<th>Activity score<sup>b</sup></th>\n<th>Examples of CYP2D6 diplotypes<sup>c</sup></th>\n<th>Implications</th>\n<th>Recommendations</th>\n<th>Classification of recommendations<sup>d</sup></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Ultrarapid metabolizer</td>\n<td>&gt;2.25</td>\n<td>&gt;2.25</td>\n<td>*1/*1xN, *1/*2xN, *2/*2xN</td>\n<td>No or insufficient evidence for drug exposure, blood pressure, and heart rate</td>\n<td>No recommendation for therapy due to insufficient or no evidence regarding drug exposure and clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Normal metabolizer</td>\n<td>1.25 ≤ x ≤ 2.25</td>\n<td>2.25<br/>2<br/>1.75<br/>1.5<br/>1.25</td>\n<td>*2x2*10<br/>*1/*1, *1/*2<br/>*1/*10x3<br/>*1/*17, *2/*29<br/>*1/*10, *1/*41, *1/*9</td>\n<td>Normal metabolism</td>\n<td>Initiate standard dosing</td>\n<td>Strong</td>\n</tr>\n<tr>\n<td>Intermediate metabolizer</td>\n<td>0 &lt; x &lt; 1.25</td>\n<td>1<br/>0.75<br/>0.5<br/>0.25</td>\n<td>*1/*5<br/>*10/*17, *29/*41<br/>*10/*10, *41/*41, *10/*41<br/>*4/*10, *4/*41</td>\n<td>No or insufficient evidence for drug exposure, blood pressure, and heart rate</td>\n<td>No recommendation for therapy due to insufficient or no evidence regarding drug exposure and clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Poor metabolizer</td>\n<td>0</td>\n<td>0</td>\n<td>*3/*4, *4/*4, *5/*5, *5/*6</td>\n<td>No or insufficient evidence for drug exposure, blood pressure, and heart rate</td>\n<td>No recommendation for therapy due to insufficient or no evidence regarding drug exposure and clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Indeterminate</td>\n<td>n/a</td>\n<td>An individual carrying one or two uncertain function alleles</td>\n<td>*1/*22, *1/*25, *22/*25</td>\n<td>n/a</td>\n<td>No recommendation</td>\n<td>No recommendation</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> See the CYP2D6 Allele Frequency Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a> for ancestry-specific allele and phenotype frequencies.<br />\n<sup>b</sup> Assignment of allele function and allele activity values, including citations for allele function, can be found in the CYP2D6 Allele Definition Table and the CYP2D6 Allele Functionality Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a>. For a complete list of CYP2D6 diplotypes and predicted phenotypes, see the CYP2D6 Diplotype to Phenotype Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a>.<br />\n<sup>c</sup> Where xN represents the number of CYP2D6 gene copies.<br />\n<sup>d</sup> Rating scheme described in the Strength of Recommendations section in the <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961-supplement.pdf\" target=\"_blank\">guideline supplement</a>.</p>\n<h3 id=\"table-3-recommended-therapeutic-use-of-nebivolol-in-relation-to-cyp2d6-phenotype\">Table 3: Recommended therapeutic use of nebivolol in relation to CYP2D6 phenotype</h3>\n<p><em>Adapted from Tables 1 &amp; S10 of the guideline</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype<sup>a</sup></th>\n<th>Activity score range</th>\n<th>Activity score<sup>b</sup></th>\n<th>Examples of CYP2D6 diplotypes<sup>c</sup></th>\n<th>Implications</th>\n<th>Recommendations</th>\n<th>Classification of recommendations<sup>d</sup></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Ultrarapid metabolizer</td>\n<td>&gt;2.25</td>\n<td>&gt;2.25</td>\n<td>*1/*1xN, *1/*2xN, *2/*2xN</td>\n<td>No or insufficient evidence for drug exposure, blood pressure, and heart rate</td>\n<td>No recommendation for therapy due to insufficient or no evidence regarding drug exposure and clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Normal metabolizer</td>\n<td>1.25 ≤ x ≤ 2.25</td>\n<td>2.25<br/>2<br/>1.75<br/>1.5<br/>1.25</td>\n<td>*2x2*10<br/>*1/*1, *1/*2<br/>*1/*10x3<br/>*1/*17, *2/*29<br/>*1/*10, *1/*41, *1/*9</td>\n<td>Normal metabolism</td>\n<td>Initiate standard dosing</td>\n<td>Strong</td>\n</tr>\n<tr>\n<td>Intermediate metabolizer</td>\n<td>0 &lt; x &lt; 1.25</td>\n<td>1<br/>0.75<br/>0.5<br/>0.25</td>\n<td>*1/*5<br/>*10/*17, *29/*41<br/>*10/*10, *41/*41, *10/*41<br/>*4/*10, *4/*41</td>\n<td>Decreased metabolism of nebivolol leading to a small increase in drug exposure; it is unclear whether this results in clinically significant changes in heart rate and blood pressure</td>\n<td>No recommendation for therapy due to insufficient evidence regarding drug exposure and clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Poor metabolizer</td>\n<td>0</td>\n<td>0</td>\n<td>*3/*4, *4/*4, *5/*5, *5/*6</td>\n<td>Decreased metabolism of nebivolol leading to increased drug exposure; it is unclear whether this results in clinically significant changes in heart rate and blood pressure</td>\n<td>No recommendation for therapy due to insufficient or no evidence regarding drug exposure and clinical effectiveness</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>Indeterminate</td>\n<td>n/a</td>\n<td>An individual carrying one or two uncertain function alleles</td>\n<td>*1/*22, *1/*25, *22/*25</td>\n<td>n/a</td>\n<td>No recommendation</td>\n<td>No recommendation</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> See the CYP2D6 Allele Frequency Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a> for ancestry-specific allele and phenotype frequencies.<br />\n<sup>b</sup> Assignment of allele function and allele activity values, including citations for allele function, can be found in the CYP2D6 Allele Definition Table and the CYP2D6 Allele Functionality Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a>. For a complete list of CYP2D6 diplotypes and predicted phenotypes, see the CYP2D6 Diplotype to Phenotype Table on the <a href=\"https://www.pharmgkb.org/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a>.<br />\n<sup>c</sup> Where xN represents the number of CYP2D6 gene copies.<br />\n<sup>d</sup> Rating scheme described in the Strength of Recommendations section in the <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961-supplement.pdf\" target=\"_blank\">guideline supplement</a>.</p>\n",
      "version" : 1
    },
    "version" : 2
  }
}